Regulatory tracker
Peptide & GLP-1 Regulatory Status
Where each compound stands with the FDA, compounding rules, and anti-doping bodies — in one place. Sort or filter to find what you need. We verify every entry by hand against primary sources.
Last reviewed June 22, 2026 · monitored weekly
All
Approved
Rx only
Under review
Not approved
How to read this: "Status" reflects U.S. regulatory standing. Many peptides are sold "for research use only" and are not approved for human use. Anti-doping bans (WADA) apply to competitive athletes. Informational, not legal advice.
Approved
Prescription only
Under review
Not approved
| Compound ▲▼ | Type ▲▼ | Status ▲▼ | Detail | Next review ▲▼ | Verified ▲▼ |
|---|---|---|---|---|---|
Semaglutide Ozempic / Wegovy |
GLP-1 | Approved | FDA-approved (diabetes & weight). Compounded versions restricted. |
— | Jun 20, 2026 |
Tirzepatide Mounjaro / Zepbound |
GLP-1 | Approved | FDA-approved (diabetes & weight). |
— | Jun 20, 2026 |
Tesamorelin Egrifta |
Peptide | Rx only | FDA-approved for HIV lipodystrophy; prescription only. |
— | Jun 12, 2026 |
BPC-157 Body protection compound |
Peptide | Not approved | Not approved. On FDA compounding risk list; PCAC reviewed. |
Jul 23, 2026 | Jun 19, 2026 |
Not legal advice
Regulatory status changes and varies by country. We verify entries against FDA, PCAC, and WADA sources and stamp each with a "verified" date, but always confirm current status yourself before acting. Nothing here is medical or legal advice.